Mon, Oct 20, 2014, 4:52 AM EDT - U.S. Markets open in 4 hrs 38 mins

Recent

% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

dinepat203 468 posts  |  Last Activity: Oct 17, 2014 4:07 PM Member since: Sep 29, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • dinepat203 dinepat203 Oct 17, 2014 4:07 PM Flag

    What happened to 2 Patients clinical trial (2006) on DMD ?

  • Reply to

    3.47 high of day coming

    by chimewire Oct 17, 2014 3:37 PM
    dinepat203 dinepat203 Oct 17, 2014 3:57 PM Flag

    This is pure fraud company

  • Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
    Filoviruses are emerging pathogens and causative agents of viral haemorrhagic fever. Case fatality rates of filovirus disease outbreaks are among the highest reported for any human pathogen, exceeding 90% (ref. 1). Licensed therapeutic or vaccine products are not available to treat filovirus diseases. Candidate therapeutics previously shown to be efficacious in non-human primate disease models are based on virus-specific designs and have limited broad-spectrum antiviral potential. Here we show that BCX4430, a novel synthetic adenosine analogue, inhibits infection of distinct filoviruses in human cells. Biochemical, reporter-based and primer-extension assays indicate that BCX4430 inhibits viral RNA polymerase function, acting as a non-obligate RNA chain terminator. Post-exposure intramuscular administration of BCX4430 protects against Ebola virus and Marburg virus disease in rodent models. Most importantly, BCX4430 completely protects cynomolgus macaques from Marburg virus infection when administered as late as 48 hours after infection. In addition, BCX4430 exhibits broad-spectrum antiviral activity against numerous viruses, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. This is the first report, to our knowledge, of non-human primate protection from filovirus disease by a synthetic drug-like small molecule. We provide additional pharmacological characterizations supporting the potential development of BCX4430 as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats.
    Travis K. Warren, Jay Wells, Rekha G. Panchal, Kelly S. Stuthman, Nicole L. Garza, Sean A. Van Tongeren, Lian #$%$, Cary J. Retterer, Brett P. Eaton, Gianluca Pegoraro, Shelley Honnold, Shanta Bantia, Pravin Kotian, Xilin Chen, Brian R. Taubenheim, Lisa S. Welch, Dena M. Minning, Yarlagadda S. Babu

  • dinepat203 dinepat203 Oct 17, 2014 2:06 PM Flag

    I like this article as this has TRUE information and not according to situation like todays date. If this article was published yesterday BCRX would have been $50.

  • Reply to

    EMA on 24th October is 100%

    by dinepat203 Oct 17, 2014 1:33 PM
    dinepat203 dinepat203 Oct 17, 2014 2:04 PM Flag

    Do you read properly ? Approval and Feedback makes sense for you?

  • dinepat203 dinepat203 Oct 17, 2014 1:53 PM Flag

    GSK is out because they are approaching BCRX.....It works.

  • dinepat203 dinepat203 Oct 17, 2014 1:51 PM Flag

    But where???????????? Yesterday or Day before ....? LOL

  • In tests conducted at USAMRIID, BCX4430 protected animals against parenteral exposures to Marburg, Ebola and Rift Valley Fever viruses and from exposures to aerosolized Marburg virus, an experimental condition designed to mimic an exposure scenario that could result during a bioterrorist attack.

    BCX4430, a viral RNA-dependent RNA polymerase (RdRp) inhibitor, is being developed as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BCRX for the development of BCX4430 as a treatment for Marburg virus disease. In 2013, NIAID awarded funding of $7.5 million to BCRX, and total funding of up to $22.0 million, if all contract options are exercised. The goals of this contract are to file investigational new drug (IND) applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, and to conduct Phase 1 human clinical trials.

  • Orexigen did obtain positive feedback from the EMA about Contrave in February this year.

  • dinepat203 dinepat203 Oct 17, 2014 1:29 PM Flag

    Developed by BCRX, BCX4430 has demonstrated antiviral activity in testing conducted at BCRX Utah State University/NIAID and USAMRIID. BCX4430 has been shown to be active against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.

    In tests conducted at USAMRIID, BCX4430 protected animals against parenteral exposures to Marburg, Ebola and Rift Valley Fever viruses and from exposures to aerosolized Marburg virus, an experimental condition designed to mimic an exposure scenario that could result during a bioterrorist attack.

    BCX4430, a viral RNA-dependent RNA polymerase (RdRp) inhibitor, is being developed as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BCRX for the development of BCX4430 as a treatment for Marburg virus disease. In 2013, NIAID awarded funding of $7.5 million to BCRX, and total funding of up to $22.0 million, if all contract options are exercised. The goals of this contract are to file investigational new drug (IND) applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, and to conduct Phase 1 human clinical trials.

  • Developed by BCRX, BCX4430 has demonstrated antiviral activity in testing conducted at BCRX Utah State University/NIAID and USAMRIID. BCX4430 has been shown to be active against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.

    In tests conducted at USAMRIID, BCX4430 protected animals against parenteral exposures to Marburg, Ebola and Rift Valley Fever viruses and from exposures to aerosolized Marburg virus, an experimental condition designed to mimic an exposure scenario that could result during a bioterrorist attack.

    BCX4430, a viral RNA-dependent RNA polymerase (RdRp) inhibitor, is being developed as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BCRX for the development of BCX4430 as a treatment for Marburg virus disease. In 2013, NIAID awarded funding of $7.5 million to BCRX, and total funding of up to $22.0 million, if all contract options are exercised. The goals of this contract are to file investigational new drug (IND) applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, and to conduct Phase 1 human clinical trials.

  • Reply to

    SRPT Fraud PR.....BS

    by dinepat203 Oct 17, 2014 12:50 PM
    dinepat203 dinepat203 Oct 17, 2014 1:20 PM Flag

    But Where ???????????

  • dinepat203 dinepat203 Oct 17, 2014 12:53 PM Flag

    Black Gold Knocks

  • dinepat203 by dinepat203 Oct 17, 2014 12:50 PM Flag

    Where? how long trials ? BS ....

  • BCRX recently reported the online publication in the journal Nature of extensive laboratory and nonclinical characterizations of BCX4430, including efficacy results in animal models of infection with Marburg virus and Ebola virus, two highly virulent pathogens responsible for viral hemorrhagic fever diseases.

  • dinepat203 dinepat203 Oct 17, 2014 12:45 PM Flag

    This Dallas Nurse released u tube video laughing at the SRPT and Authorities......

    "Another Dallas nurse, Amber Vinson, was diagnosed with Ebola on Tuesday, giving rise to concerns that the authorities may not be able to control the virus from spreading. "

  • dinepat203 dinepat203 Oct 17, 2014 12:37 PM Flag

    Filoviruses, such as Ebola virus and Marburg virus, are extremely virulent. These pathogens are classified as Category A Bioterrorism Agents by the Centers for Disease Control and Prevention. Marburg virus is a member of the family Filoviridae, along with Ravn virus, Ebola virus, Sudan virus and Bundibugyo virus, all of which cause severe viral hemorrhagic fevers in humans.

    Ebola virus disease, formerly known as Ebola haemorrhagic fever, is a severe, often fatal illness in humans, characterized by the sudden onset of fever, intense weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhoea, rash, impaired kidney and liver function, and in some cases, both internal and external bleeding. Laboratory findings include low white blood cell and platelet counts and elevated liver enzymes.

    Ebola is introduced into the human population through close contact with the blood, secretions, organs or other bodily fluids of infected animals. Ebola then spreads in the community through human-to-human transmission, with infection resulting from direct contact (through broken skin or mucous membranes) with the blood, secretions, organs or other bodily fluids of infected people, and indirect contact with environments contaminated with such fluids.

    More than 120 people have died from the latest Ebola outbreak in West Africa. With no cure or vaccine, it is one of the most deadly of viruses, killing between 60% to 90% of those infected.

    Health officials do not expect the virus to go global and stress that Ebola is not easy to catch, requiring direct contact with an infected victim’s bodily fluids.

  • dinepat203 dinepat203 Oct 17, 2014 12:36 PM Flag

    You cannot KILL Virus only stop multiplications.

  • dinepat203 dinepat203 Oct 17, 2014 12:35 PM Flag

    BioCryst Pharmaceuticals (BCRX) BCX4430, a Hope in the Battle with Ebola, Dejour Energy (DEJ) Black Gold Knocks at the Door

  • safety=======? my foot -The company released Phase I clinical trial results on the safety and tolerability of its two drugs, AVI-6002 and AVI-6003, which are being investigated as treatments for the Ebola virus and Marburg virus, respectively. The results showed “no clinically significant or dose-dependent effects” at “at any of the safety endpoints evaluated,” the company stated in a news release.

    Marburg Virus only BCRX has clinically established results on Monkeys.

AFFY
0.13-0.01(-6.47%)Oct 17 3:57 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
SAP SE
NYSEFri, Oct 17, 2014 4:02 PM EDT
NewLink Genetics Corporation
NasdaqGMFri, Oct 17, 2014 4:00 PM EDT